Journal of Multiple Sclerosis

Two-year Assessment of the Efficacy and Safety of Ocrelizumab in Switching Patients from Other Disease Modifying Therapies

Terzi Murat, Boz Cavit, Demir Caner Feyz, Cilingir Vedat* and Helvaci Elif Merve

Neuroinflammation in Parkinson’s disease (PD)

Elyna Joy*

Cognitive Decline in Older Multiple Sclerosis Patients

Jin Yong*

DOI: 10.35248/2376 0389.22.9.12.480

Dementia and Multiple Sclerosis

Andrew Spencer*

DOI: 10.35248/2376 0389.22.9.12.479